Related Experiment Video

Updated: Jan 7, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K

PANoptosis: a potential target of cardiomyopathy

Mingli Sun1, Changxu Lu1, Jinwen Wei1

  • 1College of Exercise and Health, Shenyang Sport University, Shenyang, Liaoning, China.

Frontiers in Immunology
|January 2, 2026
PubMed

Insights

PANoptosis, an integrated cell death process, is emerging as a key factor in cardiomyopathy development. Targeting PANoptosis offers a promising new therapeutic strategy for this serious heart condition.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cell Death Research

Background:

  • Cardiomyopathy encompasses diverse myocardial diseases with unclear molecular pathogenesis.
  • Current treatments for cardiomyopathy are limited to palliative drug therapy.
  • Understanding molecular pathways is crucial for developing effective cardiomyopathy interventions.

Purpose of the Study:

  • To review the association between PANoptosis activation and cardiomyopathy.
  • To explore PANoptosis as a potential therapeutic target for cardiomyopathy.
  • To summarize current research on PANoptosis in myocardial disease.

Main Methods:

  • Literature review of studies on programmed cell death (PCD) and cardiomyopathy.
  • Analysis of the role of pyroptosis, apoptosis, and necroptosis in heart disease.
  • Synthesis of research on PANoptosis as an integrated cell death process.

Main Results:

  • PANoptosis, involving pyroptosis, apoptosis, and necroptosis, is increasingly recognized in cardiomyopathy.
  • The interplay of different PCD forms in PANoptosis is linked to cardiomyopathy progression.
  • PANoptosis activation is a significant mediator in the pathogenesis of cardiomyopathy.

Conclusions:

  • PANoptosis represents a novel and critical mechanism in cardiomyopathy.
  • Targeting PANoptosis presents a promising therapeutic avenue for improving cardiomyopathy prognosis.
  • Further research into PANoptosis pathways could lead to innovative treatment strategies for heart disease.
Keywords:
PANoptosisPANoptosomecardiomyopathypotential targetprogrammed cell death

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

4.9K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
360
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
471
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
422
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K